Summary

Eligibility
for people ages 0 months to 1 month (full criteria)
Location
at Irvine, California and other locations
Dates
study started
study ends around

Description

Summary

The purpose of this study is to determine if de-implementation of inhaled nitric oxide (iNO) in the post-natal resuscitation/stabilization phase affects the composite outcome of extracorporeal life support (ECLS) use and/or mortality, as well as ECLS use, mortality, and/or oxygenation in congenital diaphragmatic hernia (CDH) newborns and to establish the cost-effectiveness of de-implementing iNO as a therapy in the postnatal resuscitation/stabilization phase of CDH management, which will be assessed as the incremental health system costs (savings) per prevented ECLS use and/or death.

Official Title

Inhaled Nitric Oxide (iNO) for Congenital Diaphragmatic Hernia (CDH) - The "NoNO Trial" - a Multi-center, De-implementation, Stepped-wedge, Cluster-randomized Trial Within an Established Collaborative

Details

In this multi-center study, centers will use iNO per their usual protocol, and centers will then crossover to iNO de-implementation (that is, at the time of crossover, centers will stop using iNO in the initial resuscitation period). A stepped-wedge crossover study design will be used, and the timing of crossover will be cluster randomized at the level of the center.

Keywords

Congenital Diaphragmatic Hernia, CDH, Inhaled Nitric Oxide, Pulmonary Hypertension, Hernias, Diaphragmatic, Congenital, Inosine, Inhaled Nitric Oxide (iNO) use, De-implementation of Inhaled Nitric Oxide (iNO) use

Eligibility

You can join if…

Open to people ages 0 months to 1 month

  • Postnatal, live born neonates with CDH
    1. Presence of associated or additional anomalies is acceptable for inclusion
  • Bochdalek hernia location (right or left)
  • Diagnosed prior to 1 month of life
  • Born within or transferred to (within 1 week of life) a CDHSG member center participating in the trial

You CAN'T join if...

  • CDH diagnosis after 1 month of age
  • Morgagni diaphragmatic hernia (central / anterior-medial diaphragmatic defect location)
  • Transferred to a CDH Study Group (CDHSG) member center after 1 week of life
  • Patients without potential access to iNO

Locations

  • University of California-Irvine & Children's Hospital of Orange County (UC-CHOC) accepting new patients
    Irvine California 92868 United States
  • University of Southern California & Children's Hospital Los Angeles (USC-CHLA) accepting new patients
    Los Angeles California 90027 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
The University of Texas Health Science Center, Houston
ID
NCT05213676
Phase
Phase 4 research study
Study Type
Interventional
Participants
Expecting 600 study participants
Last Updated